P Polakis

Summary

Affiliation: Genentech Inc
Country: USA

Publications

  1. ncbi The many ways of Wnt in cancer
    Paul Polakis
    Department of Research, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Curr Opin Genet Dev 17:45-51. 2007
  2. ncbi Activation of the Wnt pathway interferes with serum response element-driven transcription of immediate early genes
    David A Tice
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 277:6118-23. 2002
  3. ncbi EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer
    Weiguang Mao
    Department of Molecular Biology, Genentech, Inc, South San Francisco, California, USA
    Cancer Res 64:781-8. 2004
  4. ncbi Arming antibodies for cancer therapy
    Paul Polakis
    Department of Molecular Oncology, Genentech Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Curr Opin Pharmacol 5:382-7. 2005
  5. doi Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
    Jagath R Junutula
    Genentech Inc, South San Francisco, California 94080, USA
    Nat Biotechnol 26:925-32. 2008
  6. ncbi Wnt signaling and cancer
    P Polakis
    Department of Molecular Oncology, Genentech Inc, South San Francisco, California 94080 USA
    Genes Dev 14:1837-51. 2000
  7. pmc Drugging Wnt signalling in cancer
    Paul Polakis
    Department of Molecular Oncology, Genentech Inc, South San Francisco, CA 94080, USA
    EMBO J 31:2737-46. 2012
  8. pmc Formation of the blood-brain barrier: Wnt signaling seals the deal
    Paul Polakis
    Genentech, Inc, South San Francisco, CA 94080, USA
    J Cell Biol 183:371-3. 2008
  9. ncbi Casein kinase 1: a Wnt'er of disconnect
    Paul Polakis
    Department of Molecular Oncology, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Curr Biol 12:R499-R501. 2002
  10. ncbi Axin-dependent phosphorylation of the adenomatous polyposis coli protein mediated by casein kinase 1epsilon
    B Rubinfeld
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 276:39037-45. 2001

Collaborators

  • T Pham
  • W Jiang
  • R H Schwall
  • S E Fong
  • G D Frantz
  • C Sakanaka
  • James A Ernst
  • Mark S Dennis
  • Sarajane Ross
  • Hartmut Koeppen
  • Bonnee Rubinfeld
  • Ching Ching Leow
  • David A Tice
  • Jagath R Junutula
  • Yvonne Chen
  • William Mallet
  • Suzanna Clark
  • Youjun Chen
  • Venita I DeAlmeida
  • B Rubinfeld
  • M Shulewitz
  • Elizabeth Luis
  • Wei Qiang Gao
  • Sayumi Shibamoto
  • Victoria Smith
  • Yan Zhang
  • Weiguang Mao
  • Jane Winer
  • Irina Soloviev
  • D A Tice
  • W Szeto
  • Rayna Venook
  • Y Gloria Meng
  • Helga Raab
  • Richard Vandlen
  • Siao Ping Tsai
  • Amy Kim
  • Jeffrey Gorrell
  • Susan D Spencer
  • Michelle Simpson
  • Douglas D Leipold
  • Sylvia Weir
  • Richard H Scheller
  • Chien C Lee
  • Carl Ng
  • Jihong Yang
  • Henry B Lowman
  • Kevin McDorman
  • Wai Lee Wong
  • Kelly Flagella
  • Mark X Sliwkowski
  • Sunil Bhakta
  • Viswanatham Katta
  • Eileen Duenas
  • Yanmei Lu
  • Fiona Zhong
  • Terence Wong
  • Alvin Gogineni
  • Li Miao
  • Yongmei Chen
  • Sheila Bheddah
  • Archana Upadhyay
  • H Koeppen
  • Suzanna L Clark
  • I Soloviev
  • T Wu
  • David A Eberhard
  • Kenneth J Hillan
  • Patrick Dowd
  • Colin Watanabe
  • Johnny Silva
  • Mickey Williams
  • Shiuh Ming Luoh
  • Yan Zhou
  • Zemin Zhang
  • Clarissa Chui
  • Christine Tan
  • Gretchen Franz
  • Maria S Romero
  • William I Wood
  • Craig Crowley
  • Thomas D Wu
  • Peter Senter
  • Diane Pennica
  • David Wieand
  • P Mickey Williams
  • Wayne Szeto
  • Debra L Dugger
  • D Pennica
  • C W Crowley

Detail Information

Publications20

  1. ncbi The many ways of Wnt in cancer
    Paul Polakis
    Department of Research, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Curr Opin Genet Dev 17:45-51. 2007
    ..This review summarizes the reported genetic defects in the Wnt pathway, with an emphasis on their functional contribution to human tumor progression...
  2. ncbi Activation of the Wnt pathway interferes with serum response element-driven transcription of immediate early genes
    David A Tice
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 277:6118-23. 2002
    ..The results indicate that Wnt signaling can repress the expression of certain immediate early genes, and that this effect is consistent with changes in gene expression observed in human colorectal tumors...
  3. ncbi EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer
    Weiguang Mao
    Department of Molecular Biology, Genentech, Inc, South San Francisco, California, USA
    Cancer Res 64:781-8. 2004
    ..Our results suggest that ephB2 is an attractive target for immunoconjugate cancer therapy...
  4. ncbi Arming antibodies for cancer therapy
    Paul Polakis
    Department of Molecular Oncology, Genentech Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Curr Opin Pharmacol 5:382-7. 2005
    ..Recent advances hold promise for improving the therapeutic index of these anti-cancer drugs...
  5. doi Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
    Jagath R Junutula
    Genentech Inc, South San Francisco, California 94080, USA
    Nat Biotechnol 26:925-32. 2008
    ....
  6. ncbi Wnt signaling and cancer
    P Polakis
    Department of Molecular Oncology, Genentech Inc, South San Francisco, California 94080 USA
    Genes Dev 14:1837-51. 2000
  7. pmc Drugging Wnt signalling in cancer
    Paul Polakis
    Department of Molecular Oncology, Genentech Inc, South San Francisco, CA 94080, USA
    EMBO J 31:2737-46. 2012
    ..A brief discussion of molecular diagnostics and possible safety concerns is also provided...
  8. pmc Formation of the blood-brain barrier: Wnt signaling seals the deal
    Paul Polakis
    Genentech, Inc, South San Francisco, CA 94080, USA
    J Cell Biol 183:371-3. 2008
    ..Such mechanistic insight has implications for a variety of neuropathological states in which the BBB is breached...
  9. ncbi Casein kinase 1: a Wnt'er of disconnect
    Paul Polakis
    Department of Molecular Oncology, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Curr Biol 12:R499-R501. 2002
    ..New studies show that casein kinase 1 primes beta-catenin for subsequent phophorylation by glycogen synthase kinase 3...
  10. ncbi Axin-dependent phosphorylation of the adenomatous polyposis coli protein mediated by casein kinase 1epsilon
    B Rubinfeld
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 276:39037-45. 2001
    ..These results suggest that the axin-dependent phosphorylation of APC is mediated in part by CKIepsilon and is involved in the regulation of APC function...
  11. ncbi Overexpression of the retinoic acid-responsive gene Stra6 in human cancers and its synergistic induction by Wnt-1 and retinoic acid
    W Szeto
    Department of Molecular Oncology, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Cancer Res 61:4197-205. 2001
    ..The data support a model in which Wnt-1 signaling synergizes with retinoids to activate retinoic acid receptor-gamma-responsive genes in human cancers...
  12. ncbi Repressor roles for TCF-4 and Sfrp1 in Wnt signaling in breast cancer
    M Shulewitz
    Department of Molecular Oncology, Genentech Inc, South San Francisco, CA 94080, USA
    Oncogene 25:4361-9. 2006
    ..Our results indicate that both Sfrp1 and TCF-4 repress Wnt signaling in breast tissue and their downregulation contributes to the activation of Wnt signaling...
  13. ncbi A blockade in Wnt signaling is activated following the differentiation of F9 teratocarcinoma cells
    Sayumi Shibamoto
    Departments of Molecular Oncology and Molecular Biology, Genentech, Inc, South San Francisco, CA 94080 4918, USA
    Exp Cell Res 292:11-20. 2004
    ..We propose that a similar system to produce Wnt inhibitors regulates homeostasis of certain stem cell compartments in vivo...
  14. ncbi Hath1, down-regulated in colon adenocarcinomas, inhibits proliferation and tumorigenesis of colon cancer cells
    Ching Ching Leow
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, California 94080, USA
    Cancer Res 64:6050-7. 2004
    ..More importantly, this study is the first to establish a link between down-regulation of Hath1 expression and colon tumorigenesis...
  15. ncbi A role for Hath1, a bHLH transcription factor, in colon adenocarcinoma
    Ching Ching Leow
    Department of Molecular Biology, Genentech, Inc, South San Francisco, CA 94080, USA
    Ann N Y Acad Sci 1059:174-83. 2005
    ....
  16. ncbi Identification and immunotherapeutic targeting of antigens induced by chemotherapy
    Bonnee Rubinfeld
    Departments of Molecular Oncology, Pathology and Translational Oncology, Genentech, Inc, 1 DNA Way, S San Francisco, California 94080, USA
    Nat Biotechnol 24:205-9. 2006
    ..These results suggest that a positive therapeutic index may be generated for other drug combinations by immunotherapeutic targeting of chemotherapy-induced antigens...
  17. ncbi Synergistic induction of tumor antigens by Wnt-1 signaling and retinoic acid revealed by gene expression profiling
    David A Tice
    Department of Molecular Oncology, Genentech Inc, South San Francisco, California 94080, USA
    J Biol Chem 277:14329-35. 2002
    ..In principal, the therapeutic index of antibodies directed against these antigens should be enhanced by co-administration of retinoic acid...
  18. ncbi Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models
    Youjun Chen
    Department of Cancer Pathways and Targets, Genentech, Inc, South San Francisco, California 94080, USA
    Cancer Res 67:4924-32. 2007
    ..We conclude that targeting the repeat MUC16 domains, thereby increasing cell-associated levels of drug-conjugated antibody, provides superior efficacy in vitro and in vivo without compromising safety...
  19. ncbi The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo
    Venita I DeAlmeida
    Department of Cancer Pathways, Genentech Inc, South San Francisco, California 94080, USA
    Cancer Res 67:5371-9. 2007
    ..This is the first report showing the efficacy of a soluble wnt receptor as an antitumor agent and suggests that further development of wnt antagonists will have utility in treating human cancer...
  20. ncbi GEPIS--quantitative gene expression profiling in normal and cancer tissues
    Yan Zhang
    Department of Bioinformatics, Genentech Inc, South San Francisco, CA 94080, USA
    Bioinformatics 20:2390-8. 2004
    ..The vast collection of expressed sequence tags (ESTs) and the associated tissue source information provides an attractive opportunity for studying gene expression...